Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2020-08-14
Metadata
Show full item recordCitation
Boukas L, Bjornsson HT, Hansen KD. Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance. Am J Hum Genet. 2020 Sep 3;107(3):487-498. doi: 10.1016/j.ajhg.2020.07.014. Epub 2020 Aug 14. PMID: 32800095; PMCID: PMC7477270.Abstract
The aggregation and joint analysis of large numbers of exome sequences has recently made it possible to derive estimates of intolerance to loss-of-function (LoF) variation for human genes. Here, we demonstrate strong and widespread coupling between genic LoF intolerance and promoter CpG density across the human genome. Genes downstream of the most CpG-rich promoters (top 10% CpG density) have a 67.2% probability of being highly LoF intolerant, using the LOEUF metric from gnomAD. This is in contrast to 7.4% of genes downstream of the most CpG-poor (bottom 10% CpG density) promoters. Combining promoter CpG density with exonic and promoter conservation explains 33.4% of the variation in LOEUF, and the contribution of CpG density exceeds the individual contributions of exonic and promoter conservation. We leverage this to train a simple and easily interpretable predictive model that outperforms other existing predictors and allows us to classify 1,760 genes-which are currently unascertained in gnomAD-as highly LoF intolerant or not. These predictions have the potential to aid in the interpretation of novel variants in the clinical setting. Moreover, our results reveal that high CpG density is not merely a generic feature of human promoters but is preferentially encountered at the promoters of the most selectively constrained genes, calling into question the prevailing view that CpG islands are not subject to selection. Keywords: CpG density; CpG islands; GC content; dosage sensitivity; epigenetics; gnomAD; haploinsufficiency; loss-of-function; promoters; selection.Description
To access publisher's full text version of this article click on the hyperlink belowRights
Copyright © 2020. Published by Elsevier Inc.ae974a485f413a2113503eed53cd6c53
10.1016/j.ajhg.2020.07.014
Scopus Count
Collections
Related articles
- Contrasting chromatin organization of CpG islands and exons in the human genome.
- Authors: Choi JK
- Issue date: 2010
- Clusters of regulatory signals for RNA polymerase II transcription associated with Alu family repeats and CpG islands in human promoters.
- Authors: Oei SL, Babich VS, Kazakov VI, Usmanova NM, Kropotov AV, Tomilin NV
- Issue date: 2004 May
- Diversity of core promoter elements comprising human bidirectional promoters.
- Authors: Yang MQ, Elnitski LL
- Issue date: 2008 Sep 16
- The evolution of CpG density and lifespan in conserved primate and mammalian promoters.
- Authors: McLain AT, Faulk C
- Issue date: 2018 Apr 14
- The properties of CpG islands in the putative promoter regions of human immunoglobulin (Ig) genes.
- Authors: Liu GB, Yan H, Jiang YF, Chen R, Pettigrew JD, Zhao KN
- Issue date: 2005 Sep 26